Mandate

Vinge advises Axcel in connection with the launch of a Nordic property well-being service group

Vinge has advised the Nordic private equity firm Axcel in connection with its establishment of a new property well-being service group by creating a platform of 15 companies across Sweden and Norway. The group offers inspection, maintenance and incident management services for properties, with a focus on indoor air quality, moisture and pipes.

All group companies are entrepreneur-led, local businesses with long-standing customer relationships and a high level of expertise in areas such as indoor air quality, moisture control or pipes, and offers its services directly to property owners as well as through facility managers and insurance companies. In total, the new group employs nearly 500 people and generates revenue of more than SEK 800 million.

The transaction is subject to applicable regulatory approvals.

Vinge’s team consisted of Christina Kokko, Samra Tesser, Elsie Nassar, Robin Sultani, Nina Fathjalali, Erik Kochbati, Ida Appelgren, Alex Forsberg and Gabriel Chabo (M&A), Hanna Marberg and Amelia Rihs (Employment), Kamyar Najmi, Calle Tengwall Pagels and William Carlberg Johansson (Banking and Finance), Fredrika Hjelmberg and Siri Blomberg (Commercial Agreements, IT and GDPR), Arvid Axelryd, and Johan Gavelin (Intellectual Property), Hanna Kövamees and Lina Österberg (Real Property and Environment), Kristoffer Sällfors (Public Procurement), David Olander and Alva Chambert (EU, Competition and Regulatory), Gulestan Ali (Compliance) and Fanny Askelöf and Julia Ulander Kull (Transaction Support Coordinators).

Read the client’s press release here.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026